Institutional shares held 89 Million
3.64M calls
2.24M puts
Total value of holdings $2.85B
$116M calls
$71.9M puts
Market Cap $2.19B
70,036,896 Shares Out.
Institutional ownership 127.15%
# of Institutions 363


Latest Institutional Activity in RARE

Top Purchases

Q2 2025
Baker Bros. Advisors LP Shares Held: 2.77M ($86.7M)
Q2 2025
Norges Bank Shares Held: 984K ($30.8M)
Q2 2025
Assenagon Asset Management S.A. Shares Held: 1.16M ($36.4M)
Q2 2025
Farallon Capital Management LLC Shares Held: 898K ($28.1M)
Q2 2025
Frontier Capital Management CO LLC Shares Held: 525K ($16.4M)

Top Sells

Q2 2025
Adage Capital Partners Gp, L.L.C. Shares Held: 1.53M ($47.8M)
Q2 2025
Wellington Management Group LLP Shares Held: 1.87M ($58.6M)
Q2 2025
Avoro Capital Advisors LLC Shares Held: 330K ($10.3M)
Q2 2025
Invesco Ltd. Shares Held: 724K ($22.7M)
Q2 2025
Point72 Asset Management, L.P. Shares Held: 516K ($16.1M)

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.


Insider Transactions at RARE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
401K Shares
From 16 Insiders
Grant, award, or other acquisition 401K shares
Sell / Disposition
235K Shares
From 15 Insiders
Payment of exercise price or tax liability 2.03K shares
Bona fide gift 20.6K shares
Open market or private sale 212K shares

Track Institutional and Insider Activities on RARE

Follow Ultragenyx Pharmaceutical Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE